

Juan Gimeno Blanes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/391574/publications.pdf>

Version: 2024-02-01

132
papers

15,603
citations

57758
44
h-index

17105
122
g-index

154
all docs

154
docs citations

154
times ranked

13288
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
2	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
3	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq1 1 0.784314 rgBT /Overl...	2.2	848
4	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
5	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 873-879.	2.8	484
6	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
7	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet, The, 2001, 357, 420-424.	13.7	436
8	Natural history and familial characteristics of isolated left ventricular non-compaction. European Heart Journal, 2005, 26, 187-192.	2.2	427
9	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. European Heart Journal, 2006, 27, 1933-1941.	2.2	352
10	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 1448-1458.	2.2	346
11	Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. Journal of the American College of Cardiology, 2016, 68, 2440-2451.	2.8	340
12	Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nature Medicine, 2013, 19, 193-201.	30.7	296
13	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. Journal of the American College of Cardiology, 2002, 40, 1445-1450.	2.8	285
14	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	278
15	Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation. Journal of the American College of Cardiology, 2008, 51, 818-825.	2.8	256
16	Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2007, 50, 2399-2403.	2.8	254
17	Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart, 2005, 92, 785-791.	2.9	235
18	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. Journal of Clinical Investigation, 2003, 111, 209-216.	8.2	169

#	ARTICLE	IF	CITATIONS
19	Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2419-2426.	2.8	167
20	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2009, 30, 2599-2605.	2.2	160
21	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>European Heart Journal</i> , 2014, 35, 2279-2284.	2.2	154
22	Genetics of hypertrophic cardiomyopathy: A review of current state. <i>Clinical Genetics</i> , 2018, 93, 3-14.	2.0	130
23	Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. <i>Heart</i> , 2005, 91, 920-925.	2.9	126
24	Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy ($\text{HCM} \rightarrow \text{Tj ETQq00rgBT} / \text{Overlock 101}$)	7.1	114
25	Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. <i>Heart Rhythm</i> , 2015, 12, 766-773.	0.7	111
26	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1076-1096.	7.1	96
27	The Cardiomyopathy Registry of the EUROSobservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. <i>European Heart Journal</i> , 2018, 39, 1784-1793.	2.2	94
28	Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype. <i>Europace</i> , 2014, 16, 1838-1846.	1.7	87
29	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2013, 34, 2529-2537.	2.2	84
30	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 85-91.	2.7	80
31	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. <i>European Heart Journal</i> , 2015, 36, 1367-1370.	2.2	75
32	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the <i>TTN</i> Gene. <i>Circulation: Heart Failure</i> , 2020, 13, e006832.	3.9	75
33	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. <i>Journal of the American College of Cardiology</i> , 2004, 44, 398-405.	2.8	72
34	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. <i>Heart</i> , 2017, 103, 672-678.	2.9	71
35	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. <i>JAMA Cardiology</i> , 2020, 5, 73.	6.1	69
36	A new <i>KCNQ1</i> mutation at the S5 segment that impairs its association with KCNE1 is responsible for short QT syndrome. <i>Cardiovascular Research</i> , 2015, 107, 613-623.	3.8	67

#	ARTICLE	IF	CITATIONS
37	Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 240, 265-270.	1.7	66
38	Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 625-635.	0.6	60
39	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2457-2467.	2.8	59
40	Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. <i>Heart</i> , 2010, 96, 1980-1984.	2.9	58
41	Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. <i>International Journal of Cardiology</i> , 2020, 307, 101-108.	1.7	56
42	Phenotype and prognostic correlations of the converter region mutations affecting the $\tilde{\beta}^2$ myosin heavy chain. <i>Heart</i> , 2015, 101, 1047-1053.	2.9	54
43	Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study). <i>American Journal of Cardiology</i> , 2015, 116, 894-899.	1.6	46
44	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels to Predict Exercise Capacity in Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2006, 98, 515-519.	1.6	42
45	Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 82-90.	1.0	42
46	Efficacy of percutaneous closure of patent foramen ovale: comparison among three commonly used occluders. <i>Heart</i> , 2011, 97, 394-399.	2.9	42
47	Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 248, 232-238.	1.7	41
48	Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. <i>European Heart Journal</i> , 2022, 43, 3053-3067.	2.2	41
49	Sex-related differences in cardiomyopathies. <i>International Journal of Cardiology</i> , 2019, 286, 239-243.	1.7	39
50	Penetrance and Risk Profile in Inherited Cardiac Diseases Studied in a Dedicated Screening Clinic. <i>American Journal of Cardiology</i> , 2009, 104, 406-410.	1.6	38
51	Percutaneous coronary intervention with rotational atherectomy for severely calcified unprotected left main: Immediate and two-year follow-up results. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 215-220.	1.7	36
52	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2006, 27, 3073-3073.	2.2	34
53	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. <i>Journal of Cardiac Failure</i> , 2008, 14, 414-419.	1.7	33
54	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. <i>Heart</i> , 2019, 105, heartjnl-2018-313700.	2.9	31

#	ARTICLE	IF	CITATIONS
55	A mutation in the Zéline Cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. <i>Clinical Genetics</i> , 2015, 88, 172-176.	2.0	28
56	Intervencionismo coronario en lesiones severamente calcificadas mediante aterectomía rotacional y stent liberador de paclitaxel: resultados tras un año de seguimiento. <i>Revista Espanola De Cardiologia</i> , 2010, 63, 107-110.	1.2	27
57	Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram?. <i>Heart Rhythm</i> , 2021, 18, 79-87.	0.7	26
58	RNA sequencing-based transcriptome profiling of cardiac tissue implicates novel putative disease mechanisms in FLNC-associated arrhythmogenic cardiomyopathy. <i>International Journal of Cardiology</i> , 2020, 302, 124-130.	1.7	23
59	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. <i>ESC Heart Failure</i> , 2021, 8, 95-105.	3.1	23
60	Mutation in <i>JPH2</i> cause dilated cardiomyopathy. <i>Clinical Genetics</i> , 2016, 90, 468-469.	2.0	20
61	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. <i>Cardiovascular Research</i> , 2022, 118, 1466-1478.	3.8	20
62	Unclassifiable arrhythmic cardiomyopathy associated with Emeryâ€“Dreifuss caused by a mutation in <i>FHL1</i> . <i>Clinical Genetics</i> , 2016, 90, 171-176.	2.0	19
63	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	19
64	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. <i>ESC Heart Failure</i> , 2020, 7, 3013-3021.	3.1	19
65	A study of the <i>i>SCN5A</i> gene in a cohort of 76 patients with Brugada syndrome. <i>Clinical Genetics</i> , 2013, 83, 530-538.	2.0	17
66	COMPUTER ASSISTED RETINAL VESSEL TORTUOSITY EVALUATION IN NOVEL MUTATION FABRY DISEASE. <i>Retina</i> , 2017, 37, 592-603.	1.7	17
67	Soluble and Particulate Organophosphorus Neuropathy Target Esterase in Brain and Sciatic Nerve of the Hen, Cat, Rat, and Chick. <i>Journal of Neurochemistry</i> , 1993, 61, 2164-2168.	3.9	16
68	In-Hospital and Long-Term Mortality in Women With Acute Myocardial Infarction Treated by Primary Angioplasty. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 1113-1122.	0.6	16
69	Somatic <i>MYH7</i> , <i>MYBPC3</i> , <i>TPM1</i> , <i>TNNT2</i> , and <i>TNNI3</i> Mutations in Sporadic Hypertrophic Cardiomyopathy. <i>Circulation Journal</i> , 2013, 77, 2358-2365.	1.6	15
70	Heterophile antibodies produce spuriously elevated concentrations of cardiac Troponin I in patients with <i>Legionella pneumophila</i> . <i>Clinical Biochemistry</i> , 2005, 38, 584-587.	1.9	14
71	Plan of Action for Inherited Cardiovascular Diseases: Synthesis of Recommendations and Action Algorithms. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 300-309.	0.6	14
72	Backscatter evaluation of myocardial functional and textural findings in children with right ventricular pressure and/or volume overload. <i>American Journal of Cardiology</i> , 2004, 93, 594-597.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Eco-Doppler de ejercicio en pacientes con miocardiopatía hipertrófica. Factores determinantes de la limitación funcional. <i>Revista Espanola De Cardiología</i> , 2013, 66, 98-103.	1.2	12
74	ALC12-CDG: An unusual patient without intellectual disability and facial dysmorphism, and with a novel variant. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1304.	1.2	12
75	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. <i>Revista Espanola De Cardiología (English Ed)</i> , 2006, 59, 537-544.	0.6	11
76	Heat stroke, an unusual trigger of Brugada electrocardiogram. <i>American Journal of Emergency Medicine</i> , 2009, 27, 634.e1-634.e3.	1.6	11
77	Características de la muerte súbita en las cardiopatías hereditarias. <i>Revista Espanola De Cardiología</i> , 2010, 63, 268-276.	1.2	11
78	Ablación septal alcohólica en la miocardiopatía hipertrófica, una oportunidad para aprovechar. <i>Revista Espanola De Cardiología</i> , 2012, 65, 314-318.	1.2	11
79	D242N, a KV7.1 LQTS mutation uncovers a key residue for IKs voltage dependence. <i>Journal of Molecular and Cellular Cardiology</i> , 2017, 110, 61-69.	1.9	11
80	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2020, 7, 3601-3609.	3.1	11
81	A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain. <i>Revista Espanola De Cardiología (English Ed)</i> , 2017, 70, 105-114.	0.6	10
82	Genetics of feline hypertrophic cardiomyopathy. <i>Clinical Genetics</i> , 2020, 98, 203-214.	2.0	10
83	Prognostic value of the Thrombolysis in Myocardial Infarction risk score in a unselected population with chest pain. Construction of a new predictive model. <i>American Journal of Emergency Medicine</i> , 2008, 26, 439-445.	1.6	8
84	Unusual presentation of acute coronary syndrome. Bilateral coronary dissection after car accident. <i>American Journal of Emergency Medicine</i> , 2009, 27, 1024.e3-1024.e5.	1.6	7
85	Mutación p.Arg14del en fosfolambán en una familia española con miocardiopatía arritmogénica: evidencia de una mutación europea fundadora. <i>Revista Espanola De Cardiología</i> , 2015, 68, 346-349.	1.2	7
86	Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: An Opportunity to Be Taken. <i>Revista Espanola De Cardiología (English Ed)</i> , 2012, 65, 314-318.	0.6	6
87	Phospholamban p.arg14del Mutation in a Spanish Family With Arrhythmogenic Cardiomyopathy: Evidence for a European Founder Mutation. <i>Revista Espanola De Cardiología (English Ed)</i> , 2015, 68, 346-349.	0.6	6
88	Fenotipo heterogéneo del síndrome de QT largo causado por la mutación KCNH2-H562R: importancia del estudio genético familiar. <i>Revista Espanola De Cardiología</i> , 2015, 68, 861-868.	1.2	6
89	Impact of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry. <i>ESC Heart Failure</i> , 2022, 9, 2189-2198.	3.1	6
90	Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype. <i>Medicina Clínica</i> , 2014, 142, 497-504.	0.6	5

#	ARTICLE	IF	CITATIONS
91	Miocardiopatía hipertrófica. Medicina Clínica, 2018, 150, 434-442.	0.6	5
92	Trabeculated Myocardium in Hypertrophic Cardiomyopathy: Clinical Consequences. Journal of Clinical Medicine, 2020, 9, 3171.	2.4	5
93	Embolia coronaria tras implante percutáneo de prótesis valvular aórtica. Revista Española De Cardiología, 2009, 62, 1074-1075.	1.2	4
94	Exercise Eco-Doppler in Hypertrophic Cardiomyopathy Patients. Determinant Factors of Exercise Intolerance. Revista Española De Cardiología (English Ed), 2013, 66, 98-103.	0.6	4
95	Arrhythmogenic right ventricular cardiomyopathy. Lancet, The, 2015, 385, 662.	13.7	4
96	Unexpected autopsy findings after sudden cardiac death: Cardiovascular myxoedema and endocardial fibroelastosis. International Journal of Cardiology, 2015, 182, 281-283.	1.7	4
97	Value of the “Standing Test” in the Diagnosis and Evaluation of Beta-blocker Therapy Response in Long QT Syndrome. Revista Española De Cardiología (English Ed), 2017, 70, 907-914.	0.6	4
98	Genetic Factors Involved in Cardiomyopathies and in Cancer. Journal of Clinical Medicine, 2020, 9, 1702.	2.4	4
99	Towards an Enhanced Tool for Quantifying the Degree of LV Hyper-Trabeculation. Journal of Clinical Medicine, 2021, 10, 503.	2.4	4
100	An R1632C variant in the SCN5A gene causing Brugada syndrome. Molecular Medicine Reports, 2016, 13, 4677-4680.	2.4	3
101	Hypertrophic or hypertensive cardiomyopathy?. International Journal of Cardiology, 2016, 203, 891-892.	1.7	3
102	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 134-142.	4.0	3
103	Detection and estimation of T wave alternans with matched filter and nonparametric bootstrap test. , 2008, .	2	
104	Characteristics of Sudden Death in Inherited Heart Disease. Revista Española De Cardiología (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		
105	Modelo de intervención coronaria percutánea primaria en la Región de Murcia. Revista Española De Cardiología Suplementos, 2011, 11, 28-34.	0.2	2
106	Heterogeneous Phenotype of Long QT Syndrome Caused by the KCNH2-H562R Mutation: Importance of Familial Genetic Testing. Revista Española De Cardiología (English Ed), 2015, 68, 861-868.	0.6	2
107	Penetrancia familiar en la parada cardíaca en ausencia de cardiopatía aparente: observaciones del estudio FIVI-Gen. Cardiocore, 2016, 51, 30-36.	0.0	2
108	Valor del «test de bipedestación» en el diagnóstico y la evaluación de la respuesta al tratamiento con bloqueadores beta en el síndrome de QT largo. Revista Española De Cardiología, 2017, 70, 907-914.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance. Current Gene Therapy, 2018, 18, 246-251.	2.0	2
110	A study of the pathogenicity of variants in familial heart disease. The value of cosegregation. American Journal of Translational Research (discontinued), 2019, 11, 1724-1735.	0.0	2
111	Evidence for reciprocal network interactions between injured hearts and cancer. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	2
112	Gadolinium-Enhanced Cardiovascular Magnetic Resonance and Exercise Capacity in Hypertrophic Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2008, 61, 853-860.	0.6	1
113	CRT-177 Ulnar Artery, is it as Safe as the Radial for Cardiac Catheterization?. JACC: Cardiovascular Interventions, 2014, 7, S32.	2.9	1
114	Factor de transcripciÃ³n TBX1 en el remodelado cardiaco asociado al infarto de miocardio. Revista Espanola De Cardiologia, 2016, 69, 1042-1050.	1.2	1
115	La importancia del estudio familiar y genÃ©tico: la mutaciÃ³n p.L3778F en el receptor de la rianodina probablemente no cause un fenotipo tan grave. Revista Espanola De Cardiologia, 2016, 69, 702-704.	1.2	1
116	MiocardiopatÃa hipertrÃfica en 2018: Ã¢;en quÃ© punto estamos?. Cardiocrine, 2018, 53, 148-151.	0.0	1
117	Short QT and dilated cardiomyopathy. A phenotype with a good prognosis?. International Journal of Cardiology, 2011, 151, 356-357.	1.7	0
118	Hypertrophic cardiomyopathy or storage cardiomyopathy? Role of genetics to predict outcome. International Journal of Cardiology, 2011, 151, 380-381.	1.7	0
119	Atypical Cause of Syncope in Patients with Brugada Syndrome. The European Journal of Cardiovascular Medicine, 2013, 11, .	1.0	0
120	Author's reply. Europace, 2015, 17, 334-337.	1.7	0
121	New haplotype of Fabry disease among patients screened for left ventricular hypertrophy of unknown cause. Molecular Genetics and Metabolism, 2015, 114, S29-S30.	1.1	0
122	Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?. Expert Opinion on Orphan Drugs, 2016, 4, 1199-1206.	0.8	0
123	The TBX1 Transcription Factor in Cardiac Remodeling After Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1042-1050.	0.6	0
124	The Importance of Family-genetic Screening: The Phenotype Caused by the p.L3778F Ryanodine Receptor Mutation is Likely Less Severe Than Previously Thought. Revista Espanola De Cardiologia (English Ed), 2016, 69, 702-704.	0.6	0
125	Comentarios a los nuevos criterios internacionales para laÃ±interpretaciÃ³n del electrocardiograma delÃ©portista. Revista Espanola De Cardiologia, 2017, 70, 983-990.	1.2	0
126	IKs Computational Modeling to Enforce the Investigation of D242N, a KV7.1 LQTS Mutation. , 2017, , .	0	0

#	ARTICLE	IF	CITATIONS
127	D242N, a KV7.1 LQTS Mutation Uncovers a KEY Residue for IKS Voltage Dependence. <i>Biophysical Journal</i> , 2018, 114, 307a.	0.5	0
128	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1366-1367.	2.8	0
129	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. <i>Journal of Clinical Investigation</i> , 2003, 111, 925-925.	8.2	0
130	Hypertrophic Obstructive Cardiomyopathy and Takotsubo Syndrome: Could They Coexist?. <i>Archives of Cardiovascular Imaging</i> , 2015, 3, .	0.2	0
131	Factores modificadores del fenotipo en la miocardiopatía hipertrófica. Respuesta. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 770-771.	1.2	0
132	Reversal of Acute Pulmonary Oedema with Beta-blockers in Hypertrophic Cardiomyopathy. <i>European Journal of Echocardiography</i> , 2003, 4, 71-72.	2.3	0